Corvus Pharmaceuticals/CRVS

$1.53

-6.32%
-
1D1W1MYTD1YMAX

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Ticker

CRVS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Miller

Employees

28

Headquarters

Burlingame, United States

CRVS Metrics

BasicAdvanced
$75.03M
Market cap
-
P/E ratio
-$0.56
EPS
1.05
Beta
-
Dividend rate
$75.03M
1.04587
$4.19
$0.98
202.15K
4.07
-6.33%
-47.51%
-57.02%
-56.21%
1.94
1.94
36.42%

What the Analysts think about CRVS

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
398.69% upside
High $12.00
Low $3.50
$1.53
Current price
$7.63
Average price target

CRVS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-6.6M
10%
Profit margin
0%
-

CRVS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 17.65%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.14
-$0.12
-$0.14
-
Expected
-$0.16
-$0.14
-$0.12
-$0.12
-$0.12
Surprise
8.28%
0.54%
-1.64%
17.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals (CRVS) has a market cap of $75.03M as of April 14, 2024.

What is the P/E ratio for Corvus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of April 14, 2024.

Does Corvus Pharmaceuticals stock pay dividends?

No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Corvus Pharmaceuticals dividend payment date?

Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Corvus Pharmaceuticals?

Corvus Pharmaceuticals (CRVS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Corvus Pharmaceuticals stock price target?

The target price for Corvus Pharmaceuticals (CRVS) stock is $7.63, which is 398.69% above the current price of $1.53. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Corvus Pharmaceuticals stock

Buy or sell Corvus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing